Page 99 - 2019_04-Haematologica-web

New Drosophila model for chronic myeloid leukemia
Acknowledgments
We thank L. Giardino, V.A. Baldassarro, C. Mangano, and L. Calzà (Fondazione IRET, Ozzano dell’Emilia-Bologna, Italy) for assistance with the confocal microscopy analysis; D. Manzoni and M. Voltattorni for excellent technical help; M. Capovilla and the Trans-FlyER, Startup Company, Ferrara, Italy for generating the BCR-ABL1 kinase-dead transgenic lines. Drosophila lines were
obtained from the Bloomington Drosophila Stock Center-BDSC (NIH P40OD018537) and primary antibodies from the Developmental Studies Hybridoma Bank (created by the NICHD of the NIH and maintained at The University of Iowa, Department of Biology, Iowa City, IA, USA). We thank the Italian Association for Research on Cancer (AIRC) for funding D. Cilloni (IG10005) and G. Perini (IG11400, IG15182) and for supporting this work.
References
1. CheredaB,MeloJV.Naturalcourseandbiol- ogy of CML. Ann Hematol. 2015;94 (Suppl 2):S107-121.
2. Quintas-Cardama A, Cortes J. Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood. 2009;113(8):1619-1630.
3. Gonzalez C. Drosophila melanogaster: a model and a tool to investigate malignancy and identify new therapeutics. Nat Rev Cancer. 2013;13(3):172-183.
4. Bashaw GJ, Kidd T, Murray D, Pawson T, Goodman CS. Repulsive axon guidance: Abelson and Enabled play opposing roles downstream of the roundabout receptor. Cell. 2000;101(7):703-715.
5. Grevengoed EE, Loureiro JJ, Jesse TL, Peifer M. Abelson kinase regulates epithelial mor- phogenesis in Drosophila. J Cell Biol. 2001;155(7):1185-1198.
6. Liebl EC, Forsthoefel DJ, Franco LS, et al. Dosage-sensitive, reciprocal genetic interac- tions between the Abl tyrosine kinase and the putative GEF trio reveal trio's role in axon pathfinding. Neuron. 2000;26(1):107- 118.
7. Fogerty FJ, Juang JL, Petersen J, Clark MJ, Hoffmann FM, Mosher DF. Dominant effects of the bcr-abl oncogene on Drosophila morphogenesis. Oncogene. 1999;18(1):219-232.
8. Cilloni D, Messa F, Arruga F, et al. The NF- kappaB pathway blockade by the IKK inhibitor PS1145 can overcome imatinib resistance. Leukemia. 2006;20(1):61-67.
9. McGuire SE, Mao Z, Davis RL. Spatiotemporal gene expression targeting with the TARGET and gene-switch systems in Drosophila. Sci STKE. 2004;2004 (220):pl6.
10. McGuire SE, Roman G, Davis RL. Gene expression systems in Drosophila: a synthe- sis of time and space. Trends Genet. 2004;20(8):384-391.
11. GiordaniG,BarracoM,GiangrandeA,etal. The human Smoothened inhibitor PF- 04449913 induces exit from quiescence and loss of multipotent Drosophila hematopoi-
etic progenitor cells. Oncotarget. 2016;7(34):55313-55327.
12. Cilloni D, Carturan S, Bracco E, et al. Aberrant activation of ROS1 represents a new molecular defect in chronic myelomonocytic leukemia. Leuk Res. 2013;37(5):520-530.
13. Brand AH, Perrimon N. Targeted gene expression as a means of altering cell fates and generating dominant phenotypes. Development. 1993;118(2):401-415.
14. Basler K, Yen D, Tomlinson A, Hafen E. Reprogramming cell fate in the developing Drosophila retina: transformation of R7 cells by ectopic expression of rough. Genes Dev. 1990;4(5):728-739.
15. Freeman M. Reiterative use of the EGF receptor triggers differentiation of all cell types in the Drosophila eye. Cell. 1996;87(4):651-660.
16. Robinow S, White K. The locus elav of Drosophila melanogaster is expressed in neurons at all developmental stages. Dev Biol. 1988;126(2):294-303.
17. Gertler FB, Hill KK, Clark MJ, Hoffmann FM. Dosage-sensitive modifiers of Drosophila abl tyrosine kinase function: prospero, a regulator of axonal outgrowth, and disabled, a novel tyrosine kinase sub- strate. Genes Dev. 1993;7(3):441-453.
18. Hill KK, Bedian V, Juang JL, Hoffmann FM. Genetic interactions between the Drosophila Abelson (Abl) tyrosine kinase and failed axon connections (fax), a novel protein in axon bundles. Genetics. 1995;141(2):595-606.
19. Gertler FB, Bennett RL, Clark MJ, Hoffmann FM. Drosophila abl tyrosine kinase in embryonic CNS axons: a role in axonogene- sis is revealed through dosage-sensitive interactions with disabled. Cell. 1989;58(1):103-113.
20. Gertler FB, Doctor JS, Hoffmann FM. Genetic suppression of mutations in the Drosophila abl proto-oncogene homolog. Science. 1990;248(4957):857-860.
21. Krause M, Bear JE, Loureiro JJ, Gertler FB. The Ena/VASP enigma. J Cell Sci. 2002;115(Pt 24):4721-4726.
22. Grevengoed EE, Fox DT, Gates J, Peifer M. Balancing different types of actin polymer- ization at distinct sites: roles for Abelson kinase and Enabled. J Cell Biol. 2003;163(6):1267-1279.
23. Comer AR, Ahern-Djamali SM, Juang JL, Jackson PD, Hoffmann FM. Phosphorylation of Enabled by the Drosophila Abelson tyro- sine kinase regulates the in vivo function and protein-protein interactions of Enabled. Mol Cell Biol. 1998;18(1):152-160.
24. Gertler FB, Comer AR, Juang JL, et al. enabled, a dosage-sensitive suppressor of mutations in the Drosophila Abl tyrosine kinase, encodes an Abl substrate with SH3 domain-binding properties. Genes Dev. 1995;9(5):521-533.
25. Nieborowska-Skorska M, Wasik MA, Slupianek A, et al. Signal transducer and acti- vator of transcription (STAT)5 activation by BCR/ABL is dependent on intact Src homol- ogy (SH)3 and SH2 domains of BCR/ABL and is required for leukemogenesis. J Exp Med. 1999;189(8):1229-1242.
26. de Groot RP, Raaijmakers JA, Lammers JW, Jove R, Koenderman L. STAT5 activation by BCR-Abl contributes to transformation of K562 leukemia cells. Blood. 1999;94(3):1108- 1112.
27. Bina S, Wright VM, Fisher KH, Milo M, Zeidler MP. Transcriptional targets of Drosophila JAK/STAT pathway signalling as
effectors of haematopoietic tumour forma-
tion. EMBO Rep. 2010;11(3):201-207.
28. Zeidler MP, Bach EA, Perrimon N. The roles of the Drosophila JAK/STAT pathway.
Oncogene. 2000;19(21):2598-2606.
29. Le N, Simon MA. Disabled is a putative adaptor protein that functions during signal- ing by the sevenless receptor tyrosine kinase. Mol Cell Biol. 1998;18(8):4844-4854. 30. Song JK, Kannan R, Merdes G, Singh J, Mlodzik M, Giniger E. Disabled is a bona fide component of the Abl signaling net- work. Development. 2010;137(21):3719-
3727.
31. McAvoy S, Zhu Y, Perez DS, James CD,
Smith DI. Disabled-1 is a large common fragile site gene, inactivated in multiple can- cers. Genes Chromosomes Cancer. 2008;47(2):165-174.
32. Finkielstein CV, Capelluto DG. Disabled-2: A modular scaffold protein with multifac- eted functions in signaling. Bioessays. 2016;38 (Suppl 1):S45-55.
33. Zhang Z, Chen Y, Tang J, Xie X. Frequent loss expression of dab2 and promotor hyper- methylation in human cancers: a meta- analysis and systematic review. Pak J Med Sci. 2014;30(2):432-437.
34. Holz A, Bossinger B, Strasser T, Janning W, Klapper R. The two origins of hemocytes in Drosophila. Development. 2003;130(20): 4955-4962.
35. Evans CJ, Hartenstein V, Banerjee U. Thicker than blood: conserved mechanisms in Drosophila and vertebrate hematopoiesis. Dev Cell. 2003;5(5):673-690.
36. Lanot R, Zachary D, Holder F, Meister M. Postembryonic hematopoiesis in Drosophila. Dev Biol. 2001;230(2):243-257.
37. Jung SH, Evans CJ, Uemura C, Banerjee U. The Drosophila lymph gland as a develop- mental model of hematopoiesis. Development. 2005;132(11):2521-2533.
38. Krzemien J, Dubois L, Makki R, Meister M, Vincent A, Crozatier M. Control of blood cell homeostasis in Drosophila larvae by the posterior signalling centre. Nature. 2007;446 (7133):325-328.
39. Lebestky T, Jung SH, Banerjee U. A Serrate- expressing signaling center controls Drosophila hematopoiesis. Genes Dev. 2003;17(3):348-353.
40. Luo H, Hanratty WP, Dearolf CR. An amino acid substitution in the Drosophila hopTum- l Jak kinase causes leukemia-like hematopoi- etic defects. EMBO J. 1995;14(7):1412-1420.
41. Minakhina S, Steward R. Melanotic mutants in Drosophila: pathways and phenotypes. Genetics. 2006;174(1):253-263.
42. Bourbon HM, Gonzy-Treboul G, Peronnet F, et al. A P-insertion screen identifying novel X-linked essential genes in Drosophila. Mech Dev. 2002;110(1-2):71-83.
43. Irving P, Ubeda JM, Doucet D, et al. New insights into Drosophila larval haemocyte
haematologica | 2019; 104(4)
727